Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-TCR-T Cells for Refractory CMV Viremia After HSCT
NCT05089838Phase 1Unknown
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMV-TCR-T cells in cytomegalovirus infection (CMV). Primary endpoint: Adverse events at 3 months. Status: unknown.
02
Drugs
CMV-TCR-T cells
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05089838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089838.